These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37301728)

  • 21. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
    André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
    Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
    Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
    Zhang X; Yang Z; An Y; Liu Y; Wei Q; Xu F; Yao H; Zhang Z
    World J Surg Oncol; 2022 Mar; 20(1):93. PubMed ID: 35331250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
    J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability.
    Wu T; Zhang X; Liu X; Cai X; Shen T; Pan D; Liang R; Ding R; Hu R; Dong J; Li F; Li J; Xie L; Wang C; Geng S; Yang Z; Xing L; Li Y
    BMC Med; 2023 Apr; 21(1):161. PubMed ID: 37106440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
    Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F
    Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.
    Serpas Higbie V; Rogers J; Hwang H; Qiao W; Xiao L; Dasari A; Mola-Rudd K; Morris VK; Wolff RA; Raghav K; Huey R; Parseghian C; Willis J; Kopetz S; Overman MJ; Johnson B
    Oncologist; 2022 Nov; 27(11):952-957. PubMed ID: 35946836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
    Taïeb J; Bouche O; André T; Le Malicot K; Laurent-Puig P; Bez J; Toullec C; Borg C; Randrian V; Evesque L; Corbinais S; Perrier H; Buecher B; Di Fiore F; Gallois C; Emile JF; Lepage C; Elhajbi F; Tougeron D;
    JAMA Oncol; 2023 Oct; 9(10):1356-1363. PubMed ID: 37535388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
    Oh CR; Kim JE; Hong YS; Kim SY; Ahn JB; Baek JY; Lee MA; Kang MJ; Cho SH; Beom SH; Kim TW
    Int J Cancer; 2022 Jun; 150(12):2038-2045. PubMed ID: 35179785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration.
    Barraud S; Tougeron D; Villeneuve L; Eveno C; Bayle A; Parc Y; Pocard M; André T; Cohen R
    Dig Liver Dis; 2023 May; 55(5):673-678. PubMed ID: 36266207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry.
    Chong LC; Townsend AR; Young J; Roy A; Piantadosi C; Hardingham JE; Roder D; Karapetis C; Padbury R; Maddern G; Moore J; Price TJ
    Target Oncol; 2019 Feb; 14(1):85-91. PubMed ID: 30659494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
    André T; Cohen R; Salem ME
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma.
    Casak SJ; Marcus L; Fashoyin-Aje L; Mushti SL; Cheng J; Shen YL; Pierce WF; Her L; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Sep; 27(17):4680-4684. PubMed ID: 33846198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors.
    Ziranu P; Pretta A; Pozzari M; Maccioni A; Badiali M; Fanni D; Lai E; Donisi C; Persano M; Gerosa C; Puzzoni M; Bardanzellu F; Ambu R; Pusceddu V; Dubois M; Cerrone G; Migliari M; Murgia S; Spanu D; Pretta G; Aimola V; Balconi F; Murru S; Faa G; Scartozzi M
    Sci Rep; 2023 Mar; 13(1):4397. PubMed ID: 36928082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
    Fucà G; Corti F; Ambrosini M; Intini R; Salati M; Fenocchio E; Manca P; Manai C; Daniel F; Raimondi A; Morano F; Corallo S; Prisciandaro M; Spallanzani A; Quarà V; Belli C; Vaiani M; Curigliano G; Cremolini C; De Braud F; Di Bartolomeo M; Zagonel V; Lonardi S; Pietrantonio F
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
    Front Immunol; 2022; 13():913483. PubMed ID: 35958603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Stemmer A; Margalit O; Serpas V; Strauss G; Thomas J; Shah P; Tau N; Levanon K; Shacham-Shmueli E; Kopetz S; Overman M; Boursi B
    Eur J Cancer; 2024 Feb; 198():113495. PubMed ID: 38157568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
    Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL
    Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.
    Buchler T; Chloupkova R; Poprach A; Fiala O; Kiss I; Kopeckova K; Dusek L; Veskrnova V; Slavicek L; Kohoutek M; Finek J; Svoboda M; Petruzelka L; Melichar B
    Cancer Manag Res; 2019; 11():359-368. PubMed ID: 30643461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.